

FDA authorizes foreign importation of Bicillin® L-A (penicillin G benzathine)

- Pfizer's <u>Bicillin L-A (penicillin G benzathine)</u> injection has been a shortage since <u>April 2023</u> due to increased demand. To bolster supply, the FDA is coordinating with Laboratories Delbert in conjunction with Provepharm and Direct Success to <u>temporarily import</u> their penicillin G benzathine product, Extencilline (benzathine benzylpenicillin), into the U.S. This product is not a FDA-approved product but is being given special authorization due to the shortage.
- Per <u>Pfizer</u>, there is limited supply of Bicillin L-A of the 1.2 million units/2mL and 2.4 million units/2mL strengths. The pediatric 600,000 unit/mL strength is not available. Pfizer estimates that supply will recover by the 2nd quarter of 2024.
- Bicillin L-A is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms.
 Infections that usually respond to intramuscular penicillin G benzathine include mild-to-moderate infection of the upper respiratory tract due to susceptible streptococci and venereal infections (e.g., syphilis).
- Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of rheumatic fever and/or chorea. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.
- At this time, no other entity except Provepharm or its distributor Direct Success is authorized by the FDA to import or distribute Extencilline in the U.S.
- Effective immediately, Provepharm will distribute the following presentations of Extencilline:

Product Description	Strength	Packaging	NDC #	Lot #	Expiration Date
Extencilline (benzathine benzylpenicillin) powder and diluent for reconstitution for injection	1,200,000 units	20 mL vials of powder for	81284-521-01	72L00127	10/31/2025
	2,400,000 units	5 mL of water for injection in ampules	81284-522-01	72L00122	

 Refer to the <u>notice</u> for information on key differences between the U.S. marketed Bicillin L-A and Extencilline.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.